Delivery Order SPE2DB20D3103-SPE2DB25FP6A4
- Not listed
- The Defense Logistics Agency awarded a $18,415.47 delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 28, 2025, with an ultimate completion date of July 29, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and represents a direct delivery of pharmaceutical products to support federal healthcare operations. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains...
- The Defense Logistics Agency awarded a delivery order valued at $5,400.47 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pens on July 25, 2025, with an ultimate completion date of July 28, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The pharmaceutical product will be performed at the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order valued at $7,657.21 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injectables on July 21, 2025, with completion scheduled for July 22, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a single delivery of the pharmaceutical product to support federal medical supply requirements. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the performing location for...
- The Defense Logistics Agency awarded a delivery order valued at $49,427.15 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 23, 2025, with completion scheduled for July 24, 2025. This competitively awarded, firm fixed-price delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The pharmaceutical product will be...
- The Defense Logistics Agency awarded a $41,453.26 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dupixent 300 mg/2 ml pens. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to the company's corporate office location in...
- The Defense Logistics Agency awarded a $8,436.25 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen medication on July 22, 2025, with an ultimate completion date of July 23, 2025. This is a firm fixed price, non-competitive delivery order executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The work will be performed at...
- The Defense Logistics Agency awarded a $9,133.25 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 ml pen injections. This is a firm fixed price delivery order with an ultimate completion date of July 29, 2025, representing a short-duration pharmaceutical supply contract. The award carries no set-aside designation, indicating it was competitively awarded through open procurement processes. AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a $29,850.86 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. The contract, designated as a firm fixed price delivery order with an ultimate completion date of July 28, 2025, will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's established...
- The Defense Logistics Agency awarded a delivery order valued at $64,225.28 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pens on July 25, 2025, with completion targeted for July 28, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitively awarded transaction under AmerisourceBergen's existing contract vehicle with DLA. The product will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $59,618.81 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pens on July 22, 2025, with completion targeted for July 23, 2025. This non-set-aside award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 and extending through December 2026. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania,...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FP6A4Delivery Order
The Defense Logistics Agency awarded a $28,068.76 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pens on July 22, 2025, with an ultimate completion date of July 23, 2025. This non-set-aside, firm fixed price contract represents a single delivery order under the company's existing indefinite delivery vehicle with DLA. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Logistics Agency's Medical Supply Chain. This delivery order is issued under AmerisourceBergen Drug Corp's DLA Troop Support Medical indefinite delivery contract (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling the contractor to supply a broad range of pharmaceutical products and medical supplies to military healthcare programs worldwide. The underlying vehicle encompasses specialty medications, brand-name and generic drugs, vaccines, and related medical commodities across multiple therapeutic domains, serving customers including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $28.1k | 7/22/25 |